An accomplished health care executive with more than 35 years of financial and corporate strategy experience, Mr. Gemignani has served in multiple CFO roles at various life sciences and pharmaceutical companies for nearly 20 years. Earlier in his career, he served in numerous global finance functions, including financial controller roles in the United States and the Asia Pacific region for Novartis Pharmaceuticals, Prudential Financial and Wyeth, which followed a lengthy tenure at Arthur Andersen.


"Gary has a well-established track record in the life sciences industry, and his expertise in both finance and operations makes him a welcome addition to our Solta leadership team," said Scott A. Hirsch, chief executive officer, Solta. "I have known Gary for several years, and I am confident his global financial experience is the right match for us as we embark upon this new chapter for Solta and launch our IPO, subject to market conditions, approvals and other factors."


"It's an exciting time to join Solta, which has a strong reputation as an innovative leader in medical aesthetics, and I look forward to working with Scott and the leadership team during this pivotal time for the company," said Mr. Gemignani.


Source: Bausch Health Companies Inc.

«« The Impact of Staffing Shortages on Patient Safety


UK Healthcare Workforce Recovery After the COVID-19 Pandemic »»



Latest Articles

Bausch Health,Gary Gemignani,Chief Financial Officer ,CFO,life sciences An accomplished health care executive with more than 35 years of financial and corporate strategy experience, Mr. Gemignani has served in multiple CFO roles at various life sciences and pharmaceutical companies for nearly 20 years.